Kalamazoo, Michigan-based Stryker received FDA clearance for the Pangea system in September 2023. On the company’s latest earnings call, CEO Kevin Lobo highlighted Pangea as a revenue growth driver in the coming quarter.
Pangea provides a comprehensive, versatile portfolio of variable-angle plating for a variety of patient populations. Stryker designed the system to enhance plate fit and screw placement. It also elevates the plating market through anatomically contoured implants in patient populations with a wide variety of fracture patterns.
Stryker says Pangea’s intuitive and streamlined instrumentation and implant trays include 20 anatomic plates and 13 utility plates. The company made them all accessible through just one platform. The system is indicated for the internal fixation and stabilization of bone fractures, osteotomies and arthrodesis in normal and osteopenic bone.
In the company’s news release, it quoted three of the 26 surgeons that it says have pioneered work with Pangea: Dr. David A. Forsh (New York), Dr. Sanjit Konda (New York) and Dr. Joseph Hsu (North Carolina). In a news release, Forsh highlighted the system’s performance and versatility. Konda noted its “intuitive design and reliability,” while Hsu called it a “game-changer.”
“The launch of the Pangea Plating System marks a significant milestone for Stryker, our customers and the patients they serve. With the addition of Pangea, Stryker is the go-to partner for everything trauma — nails, plates, external fixation devices, and more — backed by our dedicated team and exceptional service,” said Eric Tamweber, VP and GM of Stryker’s Trauma business.
